Business
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform Transformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026 LONDON and PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Avacta Therape
About this update from Avacta Group Plc
[{"type":"image","alt":"AVACTA GROUP PLC","displaySize":"","headline":null,"caption":"AVACTA GROUP PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BuJbdPFE1KPW3OqbkUSHWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b","width":300,"height":109}},"lazy":false},{"type":"text","content":"AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025","length":81,"tagName":"p"},{"type":"text","content":"AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026","length":108,"tagName":"p"},{"type":"text","content":"Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform","length":99,"tagName":"p"},{"type":"text","content":"Transformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026","length":134,"tagName":"p"},{"type":"text","content":"LONDON and PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today provides a business update on progress for the first three months of 2025 and a review of upcoming milestones.","length":367,"tagName":"p"},{"type":"text","content":"Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said: “We made a strong start to 2025, continuing to make excellent progress against all of our strategic objectives. We are very encouraged by the Phase 1 data from FAP-Dox (AVA60000) so far, which continue to show an excellent tolerability profile and increasingly durable responses in salivary gland cancers. We are now enrolling in multiple dose expansion cohorts, including triple negative breast cancer with preliminary data targeted for later in 2025.","length":526,"tagName":"p"},{"type":"text","content":"“Our pre|CISION®-enabled exatecan program (FAP-EXd, AVA6103) also continues to progress toward a Phase 1 trial initiation early next year, underscoring our deep commitment to pioneering a novel, di...